Phase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
Izokibep is a small protein molecule that acts as a selective, potent inhibitor of
interleukin-17A, to which it binds with high affinity. Izokibep has been investigated in
non-clinical and clinical studies including healthy subjects and patients with psoriasis and
psoriatic arthritis and is currently being studied in uveitis, axial spondyloarthritis and
hidradenitis suppurativa. This study investigates izokibep in subjects with active
non-infectious, intermediate-, posterior- or pan-uveitis requiring high-dose steroids.